CN114642688A - Application of ganoderma lucidum spore oil in preparing medicine for prolonging life of tumor patient - Google Patents
Application of ganoderma lucidum spore oil in preparing medicine for prolonging life of tumor patient Download PDFInfo
- Publication number
- CN114642688A CN114642688A CN202210438760.5A CN202210438760A CN114642688A CN 114642688 A CN114642688 A CN 114642688A CN 202210438760 A CN202210438760 A CN 202210438760A CN 114642688 A CN114642688 A CN 114642688A
- Authority
- CN
- China
- Prior art keywords
- ganoderma lucidum
- spore oil
- lucidum spore
- tumor
- ganoderma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 67
- 240000008397 Ganoderma lucidum Species 0.000 title claims abstract description 62
- 235000001637 Ganoderma lucidum Nutrition 0.000 title claims abstract description 62
- 239000003814 drug Substances 0.000 title abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 241000222336 Ganoderma Species 0.000 claims description 28
- 238000000926 separation method Methods 0.000 claims description 22
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 20
- 229930012538 Paclitaxel Natural products 0.000 claims description 18
- 229960004397 cyclophosphamide Drugs 0.000 claims description 18
- 229960001592 paclitaxel Drugs 0.000 claims description 18
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 18
- 238000000605 extraction Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 9
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- 238000007670 refining Methods 0.000 claims description 8
- 150000003648 triterpenes Chemical class 0.000 claims description 8
- 206010003445 Ascites Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 5
- 239000001569 carbon dioxide Substances 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 claims description 4
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 claims description 4
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 claims description 4
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000002313 intestinal cancer Diseases 0.000 claims description 2
- 201000007270 liver cancer Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000003921 oil Substances 0.000 description 60
- 235000019198 oils Nutrition 0.000 description 60
- 241000699670 Mus sp. Species 0.000 description 43
- 230000004083 survival effect Effects 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 19
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 15
- 239000002285 corn oil Substances 0.000 description 12
- 235000005687 corn oil Nutrition 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 210000000683 abdominal cavity Anatomy 0.000 description 9
- 238000002512 chemotherapy Methods 0.000 description 9
- 239000007928 intraperitoneal injection Substances 0.000 description 8
- 229940044683 chemotherapy drug Drugs 0.000 description 7
- 238000010171 animal model Methods 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 238000000465 moulding Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 4
- 210000001099 axilla Anatomy 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 210000003489 abdominal muscle Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 238000012809 post-inoculation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 238000000658 coextraction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000035777 life prolongation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 229940108949 paclitaxel injection Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/022—Refining
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B9/00—Essential oils; Perfumes
- C11B9/02—Recovery or refining of essential oils from raw materials
- C11B9/025—Recovery by solvent extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the technical field of medicines, and provides application of ganoderma lucidum spore oil in preparation of a medicine for prolonging the life of a tumor patient.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of ganoderma lucidum spore oil in preparing a medicine for prolonging the life of a tumor patient.
Background
Ganoderma lucidum is a precious product in Chinese medical treasury, has the reputation of 'immortal grass', and can be used for treating restlessness, insomnia and palpitation, cough and asthma due to lung deficiency, consumptive disease and shortness of breath, and poor appetite. The ganoderma lucidum spores are tiny spores ejected from a pileus in the growth and maturation period of the ganoderma lucidum, are germ cells of the ganoderma lucidum, and have all genetic active substances of the ganoderma lucidum. The Ganoderma spore powder has complicated chemical components, and contains polysaccharides, triterpenes, nucleosides, vitamins, sterols, alkaloids, inorganic trace elements, etc. The Ganoderma spore oil is liposoluble active substance obtained by breaking cell wall of Ganoderma spore powder and extracting with supercritical carbon dioxide, and contains triterpenes, sterols and triglycerides as main ingredients. Research shows that the material bases of the ganoderma lucidum spore oil and the ganoderma lucidum spore powder which exert the drug effect are obviously different, the ganoderma lucidum spore polysaccharide, the triterpenoid and the ganoderma lucidum spore protein in the ganoderma lucidum spore powder exert good immunoregulation activity, the anti-tumor activity of the ganoderma lucidum spore powder mainly plays a key role by the polysaccharide and the triterpenoid, wherein the polysaccharide is the main functional component of the ganoderma lucidum spore powder, and the content of the triterpenoid is lower. The ganoderma lucidum spore oil also has the effects of resisting tumors, enhancing immunity, protecting liver and the like, contains more triterpenes and a small amount of sterols, does not contain polysaccharide, and contains a large amount of triglyceride.
In recent years, the incidence of cancer shows a trend of rising year by year, and with the transformation of a novel medical mode, medical workers pay more attention to the prolongation of the tumor-bearing life cycle of patients on the basis of the tumor treatment effect, the life cycle of cancer patients in China is far lower than the international level, and the improvement of the life cycle is the problem which needs to be urgently solved in the cancer treatment in China and is the most concerned problem of the cancer patients. With the continuous and deep understanding of the tumor problems, the method for examining the curative effect by only shrinking the tumor body has more and more limitations. In malignant tumors, especially in advanced stages, patients have poor general conditions and low quality of life even if the tumor lesions are reduced or even completely relieved. As a result, the survival time is not substantially prolonged and does not actually benefit the patient. Therefore, the medical community proposes that the treatment of malignant tumor cannot simply pursue the killing rate of tumor cells, but the improvement of the life quality and the prolonging of the survival time of the patient must be concerned so as to more scientifically evaluate the actual curative effect of treating malignant tumor.
How to better improve the life quality of tumor patients, particularly patients with advanced tumors, and effectively prolong the survival time of the patients becomes an urgent problem to be solved.
Disclosure of Invention
The invention aims to provide application of ganoderma lucidum spore oil in preparing a medicament for prolonging the life of a tumor patient. Based on the reasons and the requirements, the ganoderma lucidum spore oil is found to have the new performance of prolonging the life cycle of the tumor patients, and further provides a new application of the ganoderma lucidum spore oil as a medicament, namely the application in the aspect of medicaments for prolonging the life cycle of the tumor patients.
In order to solve the technical problem, the invention adopts the following technical scheme:
application of Ganoderma spore oil in preparing medicine for prolonging life of tumor patients is provided.
The combination of chemotherapy drugs and traditional Chinese medicine is a hotspot of tumor treatment research in recent years. The research shows that the ganoderma lucidum spore oil obtained by extracting the ganoderma lucidum spore powder by supercritical carbon dioxide has the effect of obviously improving the life cycle of a tumor patient after being combined with chemotherapeutic drugs, and no relevant report is found at present.
Preferably, the tumor comprises one or more of liver cancer tumor, lung cancer tumor, gastric cancer tumor, intestinal cancer tumor, breast cancer tumor and ascites cancer tumor.
Preferably, the tumor patient is treated with a chemotherapeutic drug.
Preferably, the chemotherapeutic drug comprises one or more of cyclophosphamide and paclitaxel.
Preferably, the ganoderma spore oil contains ergosterol, triterpene, and triglyceride.
Preferably, in the ganoderma lucidum spore oil, the mass content of triglyceride is more than 70%, the mass content of triterpene is 25% -40%, the mass content of ergosterol is 0.1% -0.5%, and the water content is less than 0.25%.
A method for preparing the ganoderma lucidum spore oil comprises the following steps: and (3) taking wall-broken ganoderma lucidum spore powder, and extracting and refining by supercritical carbon dioxide to obtain the ganoderma lucidum spore oil.
Preferably, the wall-breaking rate of the wall-broken ganoderma lucidum spore powder is more than 95%.
Preferably, the extraction refining is carried out by secondary separation, and only a first-stage separation sample is reserved, so that the ganoderma lucidum spore oil is obtained.
Preferably, the conditions of the extraction essence comprise: the extraction pressure is 25-35 MPa, the extraction temperature is 40-45 ℃, the extraction time is 1-2 h, and CO is added2The flow is 40L/h, the first-stage separation pressure is 10-15 MPa, the separation temperature is 40-45 ℃, the second-stage separation pressure is 5-8 MPa, and the separation temperature is 40-45 ℃.
The invention only keeps the sample obtained by the first-stage separation, and the ganoderma lucidum spore oil is obtained. And a large amount of impurities and water are removed through separation and refining, and the obtained ganoderma lucidum spore oil is clear and transparent and has stable component content. Experiments show that the sample after the second-stage separation contains more impurities, has turbid appearance and high moisture content (about 10 percent), is easy to deteriorate and is not reserved.
Supercritical carbon dioxide extraction is a novel green extraction and separation technology which is particularly suitable for extracting fat-soluble, high-boiling point and thermosensitive substances. The Ganoderma spore oil is liposoluble active substance obtained by breaking cell wall of Ganoderma spore and extracting with supercritical carbon dioxide, and contains sterol, triterpene, triglyceride, etc. In order to obtain the target ganoderma lucidum spore oil with stable quality, the invention removes a large amount of impurities and moisture by separation and refining, the obtained ganoderma lucidum spore oil is clear and transparent, has few impurities and stable component content, ensures the stability of the material base of the ganoderma lucidum spore oil, and obviously ensures the effect.
Compared with the prior art, the implementation of the invention has the following beneficial effects:
experiments and researches on tumor-bearing mice using chemotherapeutic drugs show that the ganoderma lucidum spore oil has a remarkable effect of prolonging the life cycle of the tumor-bearing mice. The ganoderma lucidum spore oil has the beneficial effect of being used for preparing the medicine for prolonging the life cycle of a tumor patient.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention clearer, the present invention will be further described in detail with reference to specific examples so that those skilled in the art can better understand the present invention and can implement the present invention, but the examples are not intended to limit the present invention. Modifications or substitutions to methods, procedures, or conditions of the invention may be made without departing from the spirit and scope of the invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art.
Example 1
Preparation of ganoderma spore oil
The preparation method of the ganoderma lucidum spore oil comprises the following steps:
breaking cell wall of Ganoderma spore powder 500g to a cell wall breaking rate of more than 95%, and performing supercritical CO extraction2Extracting, and separating and refining to obtain the ganoderma lucidum spore oil. The extraction pressure is 25-35 MPa, the extraction temperature is 40-45 ℃, the extraction time is 1-2 h, and CO is added2The flow is 40L/h, the primary separation pressure is 10-15 MPa, the separation temperature is 40-45 ℃, the secondary separation pressure is 5-8 MPa, and the separation temperature is 40-45 ℃. Only retaining the sample obtained by the first-stage separation to obtain the ganoderma lucidum spore oil. Separating and refining to remove a large amount of impurities and water, and obtaining the Ganoderma spore oilBright and stable component content. Experiments show that the sample obtained after the second-stage separation contains more impurities, has turbid appearance and high moisture content (about 10 percent), is easy to deteriorate and is not reserved.
Example 2
Effect of Ganoderma spore oil on survival of mice with ascites carcinoma cell transplantable tumors treated with cyclophosphamide
1. Laboratory animal
ICR mice, males, weight 26 ± 2 g. Animals are raised in an SPF animal room with alternating light and shade (12h:12h) and are free to eat and drink water. The experiment was started 7 days after the animals had acclimatized in the animal house.
2. Experimental Material
The ganoderma spore oil is prepared into solution with corresponding concentration by using corn oil before administration, and is prepared for use. Cyclophosphamide (CTX), is prepared into a solution with a corresponding concentration by using normal saline before administration, and is prepared for use.
Cell lines: EAC cell line (mouse Ehrlich ascites carcinoma cell line).
3. Experimental methods
(1) Establishing a tumor-bearing mouse animal model: culturing EAC cells, selecting cells in optimal growth state, and adjusting cell concentration to 5 × 106Perml, the abdominal cavity of mice was injected under sterile conditions, and 0.2ml was injected per mouse. Subculturing in abdominal cavity for 10-12 days, collecting healthy tumor-bearing mouse with swollen abdomen, vigorous growth and no rupture, placing on a clean bench, sterilizing abdominal skin, penetrating abdominal muscle with hollow needle, extracting ascites, placing into sterile container, storing on ice block, washing with normal saline, centrifuging for 2 times, diluting with normal saline, counting, and adjusting cell concentration to 5 × 107Each mouse was injected subcutaneously with 0.2mL of the above tumor cell suspension per mouse in the axilla of the right anterior limb. At 24h post-inoculation, the group administration was started.
(2) Experiment grouping
CTX group: carrying out intragastric lavage on 16 tumor-bearing mice by using corn oil with equal volume; simultaneously, 50mg/Kg of cyclophosphamide is injected into the abdominal cavity, and the times are 2 times per week; the above administration was performed until the animal died.
Ganoderma spore oil + CTX group: intragastric administration of Ganoderma spore oil (5.1ml/Kg) in 20 tumor-bearing mice, and intraperitoneal injection of cyclophosphamide (50 mg/Kg) 2 times per week; the above administration was performed until the animal died.
(3) Influence of ganoderma lucidum spore oil on survival time and life prolonging rate of EAC solid tumor mice
The day of mouse molding is day 0, and the intragastric administration of ganoderma lucidum spore oil or corn oil is started from the first day after the molding, and the administration is continued until the death of animals. Cyclophosphamide or saline was administered to the abdominal cavity twice a week starting the first week after molding until the animals died. Counting the survival time of each group of mice, calculating the average survival time of each group, and calculating the life prolonging rate according to the following formula: the life extension rate (mean survival time of drug group-mean survival time of model group)/mean survival time of model group × 100%, and was statistically processed. .
4. Results of the experiment
The mean survival days for EAC tumor bearing mice after continuous gavage with corn oil and 2 intraperitoneal injections of cyclophosphamide (CTX group) per week was 31.5 ± 8.8 d. After continuous gavage administration of ganoderma spore oil (5.1ml/Kg) and 2 intraperitoneal injections of cyclophosphamide per week, the average survival days of mice were 37.9 ± 7.7d, which is statistically different from that of the CTX group, and the life prolongation rate was 20.2%. The results show that the ganoderma lucidum spore oil can obviously prolong the life cycle of tumor-bearing mice after the administration of chemotherapeutic drugs.
Example 3
Effect of Ganoderma spore oil on survival of H22 tumor-bearing mice receiving cyclophosphamide treatment
1. Laboratory animal
ICR mice, males, weight 26 ± 2 g. Animals are raised in an SPF animal room with alternating light and shade (12h:12h) and are free to eat and drink water. The experiment was started 7 days after the animals had acclimatized in the animal house.
2. Experimental Material
The ganoderma spore oil is prepared into solution with corresponding concentration by using corn oil before administration, and is prepared for use. Cyclophosphamide (CTX), is prepared into a solution with a corresponding concentration by using normal saline before administration, and is prepared for use.
Cell lines: h22 hepatoma carcinoma cell.
3. Experimental methods
(1) Establishing a tumor-bearing mouse animal model: culturing H22 cells, collecting cells in optimal growth state, and adjusting cell concentration to 2.5 × 106Perml, the abdominal cavity of mice was injected under sterile conditions, and 0.2ml was injected per mouse. Subculturing in abdominal cavity for 10-12 days, collecting healthy tumor-bearing mouse with swollen abdomen, vigorous growth and no rupture, placing on a clean bench, sterilizing abdominal skin, penetrating abdominal muscle with hollow needle, extracting ascites, placing into sterile container, storing on ice block, washing with normal saline, centrifuging for 2 times, diluting with normal saline, counting, and adjusting cell concentration to 2 × 107Each mouse was injected subcutaneously with 0.2mL of the above tumor cell suspension per mouse in the axilla of the right anterior limb. 5 days after inoculation, mice with accessible lumps in the axilla were selected and the group administration was started.
(2) Experiment grouping
Solvent control group: the gastric lavage is carried out on 25 tumor-bearing mice with corn oil with equal volume; simultaneously, 50mg/Kg of cyclophosphamide is injected into the abdominal cavity, and the times are 2 times per week; until the animal dies.
Ganoderma lucidum spore oil (2.72ml/Kg) + cyclophosphamide group: intragastric administration of 25 tumor-bearing mice (2.72ml/Kg) with Ganoderma spore oil once a day for 6 days, and stopping administration for 1 day; simultaneously, 50mg/Kg of cyclophosphamide is injected into the abdominal cavity, and the times are 2 times per week; the above administration was performed until the animal died.
Ganoderma lucidum spore oil (0.34ml/Kg) + cyclophosphamide group: intragastric administration of 25 tumor-bearing mice (0.34ml/Kg) with Ganoderma spore oil once a day for 6 days, and stopping administration for 1 day; simultaneously, 50mg/Kg of cyclophosphamide is injected into the abdominal cavity for 2 times per week; the above administration was performed until the animal died.
(3) Influence of ganoderma lucidum spore oil on survival time and life prolonging rate of H22 solid tumor mice
After randomly grouping tumor-bearing mice, feeding ganoderma spore oil or corn oil for intragastric administration is started, and the administration is continued until the animals die. Intraperitoneal injections of Cyclophosphamide (CTX) or normal saline were started at the same time, twice a week, until the animals died. Counting the survival time of each group of mice, calculating the average survival time of each group, and calculating the life prolonging rate according to the following formula: the life extension rate (mean survival time of drug group-mean survival time of model group)/mean survival time of model group × 100%, and was statistically processed.
4. Results of the experiment
Solvent control group H22 tumor-bearing mice were continuously gavaged with corn oil for 21 days, and were also injected with Cyclophosphamide (CTX) intraperitoneally 2 times a week, and the average survival days of the mice was 41.12 + -2.77 d. The mice are continuously gavaged with ganoderma lucidum spore oil (2.72ml/Kg), and after 2 times of intraperitoneal injection of cyclophosphamide every week, the average survival days of the mice are 53.96 +/-3.81 days which are obviously longer than that of a solvent control group (P is less than 0.05), and the life prolonging rate is 31.23%. The mice are continuously gavaged with ganoderma lucidum spore oil (0.34ml/Kg), and after 2 times of intraperitoneal injection of cyclophosphamide every week, the average survival days of the mice are 54.68 +/-3.91 d which are obviously longer than that of a solvent group (P is less than 0.05), and the life prolonging rate is 32.99%. The results suggest that the ganoderma lucidum spore oil can significantly prolong the survival time of H22 tumor-bearing mice receiving CTX chemotherapy.
Example 4
Effect of Ganoderma spore oil on survival of Lewis lung cancer-bearing mice receiving paclitaxel treatment
1. Laboratory animal
C57BL/6 mice, male, with a body mass of 22 + -4 g at the time of the experiment (5-6 weeks old). Animals are raised in an SPF animal room with alternating light and shade (12h:12h) and are free to eat and drink water. The experiment was started 7 days after the animals had acclimatized in the animal house.
2. Experimental Material
The ganoderma spore oil is prepared into solution with corresponding concentration by using corn oil before administration, and is prepared for use. Paclitaxel injection (PTX).
Cell lines: lewis lung carcinoma cells.
3. Experimental methods
(1) Establishing a tumor-bearing mouse animal model: recovering and culturing Lewis lung cancer cells, collecting cells in optimal growth state, and adjusting cell concentration to 7.5 × 106One per ml, mice were injected subcutaneously with 0.2ml of the above tumor cell suspension per mouse in the right anterior axilla. On day 5 post inoculation, the tumorigenic mice were randomly grouped by body weight.
(2) Experimental groups
Paclitaxel single use group: corn oil + PTX (20mg/Kg)
Ganoderma spore oil (high dose) combination: ganoderma spore oil (3.4ml/Kg) + PTX (20mg/Kg)
Ganoderma lucidum spore oil (low dose) combination: ganoderma spore oil (0.34ml/Kg) + PTX (20mg/Kg)
(3) Influence of ganoderma lucidum spore oil on survival time and life prolonging rate of mice with Lewis solid tumors
The day of mouse molding is day 0, and the intragastric administration of ganoderma lucidum spore oil or corn oil is started from the first day after the molding, and the administration is continued until the death of animals. Paclitaxel or saline was administered intraperitoneally from the first week after molding twice a week until the animals died. Counting the survival time of each group of mice, calculating the average survival time of each group, and calculating the life prolonging rate according to the following formula: the life extension rate (mean survival time of drug group-mean survival time of model group)/mean survival time of model group × 100%, and was statistically processed.
4. Results of the experiment
Lewis tumor-bearing mice in the paclitaxel-treated group alone were continuously gavaged with corn oil for 21 days, and were intraperitoneally injected with Paclitaxel (PTX) 2 times a week, with the average survival day of the mice being 17.68. + -. 1.42 d. The mice in the high-dose combination paclitaxel treatment group are continuously administered with ganoderma spore oil (3.4ml/Kg) by intragastric administration, and after 2 times of intraperitoneal injection of paclitaxel every week, the average survival days of the mice are 22.05 +/-1.49 days which are obviously higher than that of the solvent group (P <0.05), and the life prolonging rate is 22.89%. The low-dose combination of the ganoderma lucidum spore oil and the paclitaxel is used for mice in a paclitaxel treatment group to continuously administrate the ganoderma lucidum spore oil (0.34ml/Kg) through intragastric administration, and after 2 times of intraperitoneal injection of paclitaxel every week, the average survival days of the mice are 22.55 +/-1.43 d, which are obviously longer than that of a solvent group (P is less than 0.05), and the life prolonging rate is 27.55%. The results suggest that the ganoderma lucidum spore oil can obviously prolong the life cycle of PTX chemotherapy of tumor-bearing mice.
In conclusion, the ganoderma lucidum spore oil has the obvious effect of prolonging the life cycle of tumor-bearing mice after the administration of chemotherapeutic drugs. The ganoderma lucidum spore oil has the beneficial effect of being used for preparing the medicine for prolonging the life time of tumor-bearing mice after the chemotherapy medicine is given.
The above disclosure is only for the purpose of illustrating the preferred embodiments of the present invention and is not to be construed as limiting the scope of the present invention, therefore, the present invention is not limited by the appended claims.
Claims (10)
1. The application of ganoderma spore oil in pharmacy is characterized in that the ganoderma spore oil is used for prolonging the life of a tumor patient.
2. The use of claim 1, wherein the tumor comprises one or more of liver cancer tumor, lung cancer tumor, stomach cancer tumor, intestinal cancer tumor, breast cancer tumor, ascites cancer tumor.
3. The use of claim 1, wherein said patient is treated with a chemotherapeutic agent.
4. The use of claim 3, wherein the chemotherapeutic agent comprises one or more of cyclophosphamide and paclitaxel.
5. The use of claim 1, wherein the ganoderma lucidum spore oil comprises ergosterol, triterpenes, triglycerides.
6. The use according to claim 5, wherein the ganoderma lucidum spore oil contains more than 70% by mass of triglyceride, 25-40% by mass of triterpene, 0.1-0.5% by mass of ergosterol and less than 0.25% by mass of moisture.
7. A method for preparing the ganoderma lucidum spore oil as claimed in claim 5, comprising: and (3) taking wall-broken ganoderma lucidum spore powder, and extracting and refining by supercritical carbon dioxide to obtain the ganoderma lucidum spore oil.
8. The preparation method according to claim 7, wherein the wall-broken rate of the wall-broken ganoderma lucidum spore powder is more than 95%.
9. The method according to claim 7, wherein the ganoderma lucidum spore oil is obtained by subjecting the extractive refining to secondary separation and retaining only the primary separated sample.
10. The production method according to claim 9, wherein the conditions for the extractive purification include: the extraction pressure is 25-35 MPa, the extraction temperature is 40-45 ℃, the extraction time is 1-2 h, and CO is added2The flow is 40L/h, the first-stage separation pressure is 10-15 MPa, the separation temperature is 40-45 ℃, the second-stage separation pressure is 5-8 MPa, and the separation temperature is 40-45 ℃.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210438760.5A CN114642688A (en) | 2022-04-25 | 2022-04-25 | Application of ganoderma lucidum spore oil in preparing medicine for prolonging life of tumor patient |
| PCT/CN2022/133500 WO2023207054A1 (en) | 2022-04-25 | 2022-11-22 | Use of ganoderma lucidum spore oil in preparing a drug for prolonging survival time of tumor patients |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210438760.5A CN114642688A (en) | 2022-04-25 | 2022-04-25 | Application of ganoderma lucidum spore oil in preparing medicine for prolonging life of tumor patient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114642688A true CN114642688A (en) | 2022-06-21 |
Family
ID=81997019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210438760.5A Pending CN114642688A (en) | 2022-04-25 | 2022-04-25 | Application of ganoderma lucidum spore oil in preparing medicine for prolonging life of tumor patient |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114642688A (en) |
| WO (1) | WO2023207054A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023207054A1 (en) * | 2022-04-25 | 2023-11-02 | 广州白云山汉方现代药业有限公司 | Use of ganoderma lucidum spore oil in preparing a drug for prolonging survival time of tumor patients |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101485694A (en) * | 2009-03-03 | 2009-07-22 | 南京中科集团股份有限公司 | Method for extracting Ganoderma lucidum triterpenes components |
| CN101518551A (en) * | 2008-02-26 | 2009-09-02 | 广州汉方现代中药研究开发有限公司 | Ganoderma spore oil fat emulsion and quality control method and application thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106344627B (en) * | 2016-09-06 | 2020-01-31 | 广州普立森生物科技有限公司 | Application of ganoderma lucidum spore oil in preparation of medicine for relieving adriamycin cardiotoxicity |
| CN106692213A (en) * | 2016-12-23 | 2017-05-24 | 广州白云山汉方现代药业有限公司 | Preparation and application of ganoderma lucidum spore oil, ganoderma lucidum spore oil fat emulsion |
| CN114642688A (en) * | 2022-04-25 | 2022-06-21 | 广州白云山汉方现代药业有限公司 | Application of ganoderma lucidum spore oil in preparing medicine for prolonging life of tumor patient |
| CN114652755A (en) * | 2022-04-25 | 2022-06-24 | 广州白云山汉方现代药业有限公司 | Application of ganoderma lucidum spore oil in preparation of medicine for reducing cytotoxicity of paclitaxel NK |
-
2022
- 2022-04-25 CN CN202210438760.5A patent/CN114642688A/en active Pending
- 2022-11-22 WO PCT/CN2022/133500 patent/WO2023207054A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101518551A (en) * | 2008-02-26 | 2009-09-02 | 广州汉方现代中药研究开发有限公司 | Ganoderma spore oil fat emulsion and quality control method and application thereof |
| CN101485694A (en) * | 2009-03-03 | 2009-07-22 | 南京中科集团股份有限公司 | Method for extracting Ganoderma lucidum triterpenes components |
Non-Patent Citations (2)
| Title |
|---|
| 刘国健等: "灵芝孢子油口服乳剂对荷瘤化疗小鼠的增效减毒作用", 《肿瘤代谢与营养电子杂志》 * |
| 周晓宏等: "HPLC-ELSD法测定灵芝孢子油中三油酸甘油酯的含量", 《广东药学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023207054A1 (en) * | 2022-04-25 | 2023-11-02 | 广州白云山汉方现代药业有限公司 | Use of ganoderma lucidum spore oil in preparing a drug for prolonging survival time of tumor patients |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023207054A1 (en) | 2023-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103768534B (en) | A kind of Chinese medicine composition with antitumor activity | |
| CN104225217B (en) | A kind of Chinese medicine preparation for treating coronary heart disease and preparation method thereof | |
| EP3225234A1 (en) | Preparation containing chlorogenic acid crystal form and use thereof | |
| KR20100051032A (en) | Composition for preventing or treating cancer comprising plant stem cell line derived from cambium of panax ginseng including wild ginseng or ginseng | |
| JP2016102111A (en) | Pharmaceutical compositions considered as supplementary chemotherapy pharmaceuticals and applications thereof | |
| JP6389958B2 (en) | Medicinal use of anti-tumor for rutile pentacyclic triterpene saponins | |
| CN114642688A (en) | Application of ganoderma lucidum spore oil in preparing medicine for prolonging life of tumor patient | |
| CN104872656A (en) | Composition with health function and preparation method thereof | |
| CN1733081A (en) | Chinese medicine preparation for nourishing blood and tranquilizing mind and its preparation process | |
| CN101948473B (en) | New NEO-clerodane diterpenoid compound and application thereof | |
| KR101033671B1 (en) | Anticancer health foods including Phellinus linteus and vegetable worms | |
| CN114652755A (en) | Application of ganoderma lucidum spore oil in preparation of medicine for reducing cytotoxicity of paclitaxel NK | |
| CN101077873B (en) | Novel NEO-clerodane type diterpene compound and application thereof | |
| CN113633689A (en) | Oligogalacturonan traditional Chinese medicine composite preparation, preparation method and application | |
| KR20140080289A (en) | Composition for preventing or treating of oxidative brain injury and brain function disorder | |
| KR100892764B1 (en) | Modified ginsenoside mixture which has selective anti-lung cancer activity | |
| CN111329871A (en) | Preparation method and application of product of cordyceps militaris for preventing and treating liver cancer | |
| JP2016079163A (en) | Composition for treating tumor, and production method thereof | |
| CN105769884B (en) | A kind of pharmaceutical composition for treating lung cancer | |
| KR101000953B1 (en) | EXTRACTS OF Lespedeza cuneate G. Don AND THEIR USES | |
| TW202017578A (en) | Preparation method and pharmaceutical composition for the extarct and composition of antrodia cinnamomea. | |
| CN103877126B (en) | Knurl lid intends the pharmaceutical usage of shelf fungus and the pharmaceutical composition for the treatment of tumour | |
| CN102038190A (en) | Application of ampelopsin to preparation of anti-mutagenic health-care foods and medicaments | |
| CN1850068A (en) | Medicinal composition for treating cardio-cerebral-vascular disease and its preparing method | |
| TW200946140A (en) | Stable-type Cucurbitacin medicinal liquid compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220621 |
|
| RJ01 | Rejection of invention patent application after publication |